Hillsdale Investment Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Hillsdale Investment Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-40,000	Closed	-$720K	–	684
2020 Q3	$720K	Buy	40,000 +2,300	+6%	+$47.6K	0.07%	260
2020 Q2	$958K	Sell	37,700 -2,000	-5%	-$43.1K	0.09%	182
2020 Q1	$729K	Buy	39,700 +1,000	+3%	+$19.4K	0.09%	199
2019 Q4	$853K	Buy	+38,700	New	+$779K	0.07%	235
2019 Q1	–	Sell	-11,700	Closed	-$125K	–	714
2018 Q4	$125K	Buy	+11,700	New	+$154K	0.01%	397

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hillsdale Investment Management's DRNA Position: Q4 2020 in Review

Hillsdale Investment Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2020, closing a stake of 40,000 shares — an estimated $720K sold.

Hillsdale Investment Management first reported a position in DRNA in Q4 2018 and held it in 5 quarters. The position peaked at $958K in Q2 2020. 173 funds tracked by Wall St. Rank hold DRNA as of Q4 2020.

Hillsdale Investment Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Hillsdale Investment Management sold 40,000 Dicerna Pharmaceuticals, Inc. shares in Q4 2020, an estimated $720K.
Hillsdale Investment Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and held it in 5 quarters.
Hillsdale Investment Management's Dicerna Pharmaceuticals, Inc. position peaked at $958K in Q2 2020.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2020.

Based on Hillsdale Investment Management's 13F filing for Q4 2020, filed 9 Feb 2021.